Abstract
Purpose :
During and after chemotherapy against retinoblastoma, new tumors develop. To establish eye- and vision-preserving therapeutic options, novel therapeutic approaches should be implanted to address these new tumors. In this study, we aimed to investigate spatiotemporal dynamics of new tumor development during and after chemotherapy against retinoblastoma.
Methods :
Medical records and fundus photographs of retinoblastoma patients who visited Seoul National University Children’s Hospital from 1998 to 2014 were reviewed. Two different periods were utilized for the identification of new tumors during (from 2004 to 2014) and after (from 1998 to 2010) chemotherapy. Age at diagnosis, gender, laterality, staging, location of tumors, initial treatment, and the development of new tumors during and after chemotherapy were identified. Using Kaplan-Meier analyses, the risk of new tumor development were assessed.
Results :
1) New tumor development during chemotherapy: from 188 retinoblastoma patients (234 eyes), 78 patients (41.5%; 114 eyes, 48.7%) were identified to undergo chemotherapy. Among them, new tumors were observed in 40 patients (51.3%; 49 eyes, 43.0%): 24 patients (33 eyes) demonstrated isolated tumors, whereas, 16 patients (16 eyes) showed miliary tumors. All new tumors were identified to develop within 20 months from the initiation of the chemotherapy and in the peripheral retina. 2) New tumor development after chemotherapy: from 226 retinoblastoma patients (278 eyes), 90 patients (39.8%; 125 eyes, 45.0%) were identified to undergo chemotherapy. Among them, new tumors were observed in 7 patients (7.8%; 7 eyes, 5.6%). Mean tumor-free interval was 46.8 months (range, 11 to 137 months). New tumors developed both near the original tumors and in the previously unaffected sites.
Conclusions :
During and after chemotherapy, new tumors were observed in a group of patients. It is essential to understand the dynamics, when and where, of new tumor occurrence during and after chemotherapy for the development of novel therapeutic options against them.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.